news

CUPERTINO, Calif., June 29, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of […]

CUPERTINO, Calif., June 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020, it is terminating the License Agreement dated July 19, 2019 and a related R&D agreement between Gilead and DURECT related to the development and commercialization of a

CUPERTINO, Calif., May 28, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Jefferies 2020 Virtual Health Care Conference, Wednesday, June 3, 2020 at 10:00 a.m. EDT / 7:00 a.m. PDT.  Institutional investors and analysts that are participating in the conference may request a

— Improvements in both serum liver enzymes and liver imaging — Improvement in serum lipid profile — DUR-928 was well tolerated with no significant adverse events — Promising data support further development of DUR-928 in NASH CUPERTINO, Calif., May 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced positive topline results from its Phase 1b

Working on Proof-of-Concept Phase 2 Trial in COVID-19 Patients with Acute Liver or Kidney Injury Live Webcast of Earnings Call Today, May 11th at 4:30 p.m. ET CUPERTINO, Calif., May 11, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2020 and provided a corporate update.

CUPERTINO, Calif., May 4, 2020  DURECT Corporation (Nasdaq: DRRX) today announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, May 11, 2020. Monday May 11th  @ 4:30pm Eastern Time/ 1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13703442 Webcast: http://public.viavid.com/index.php?id=139763   About DURECT Corporation

Fourth Quarter Highlighted by Presentation of Positive DUR-928 Phase 2a Alcoholic Hepatitis Data at the Liver Meeting® 2019 Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 3, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2019 and

CUPERTINO, Calif., Feb. 26, 2020 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results and host a conference call after the market close on Tuesday, March 3, 2020. Tuesday March 3rd @ 4:30pmET/1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560

CUPERTINO, Calif., Jan. 17, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met yesterday to discuss the Class 2 New Drug Application (NDA) resubmission for POSIMIR® (bupivacaine extended-release solution). In a split vote on the key question, six

CUPERTINO, Calif., Jan. 16, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that NASDAQ has halted trading of the Company’s common stock today. The U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is holding a meeting today from 8 a.m. to 5 p.m. ET to discuss POSIMIR, an investigational